Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Brain stimulation relieves pain in fibromyalgia patients

31 Jul 2020

Extended treatment with transcranial direct current stimulation (tDCS) applied over dorsolateral prefrontal cortex (DLPFC) induces large reductions in pain in fibromyalgia patients, as shown in a study.

Twenty women (average age, 49 years) with fibromyalgia were randomized to undergo 60 sessions of home-based anodal tDCS (n=10) or sham tDCS (n=10). During active treatment, 2-mA current was applied for 30 minutes for 5 consecutive days for 12 weeks. Treatment was self-administered with a specially developed device following in-person training.

Baseline characteristics were balanced between the treatment groups. In the guessing treatment assessment, 19 patients (95.1 percent) believed receiving brain tDCS and one patient (5 percent) believed to have received sham stimulation.

The cumulative incidence of burning, tingling, itchiness, and redness in the active and sham treatment groups were 25 percent and 17 percent, respectively (p=0.165). On the other hand, the cumulative incidence of a headache, neck pain, mood swings, and concentration difficulties were 7 percent and 16 percent, respectively (p=0.046). All side effects were classified as mild.

After the first 20 sessions, active tDCS reduced cumulative pain scores by 45.65 percent relative to sham treatment (mean, 7.25 vs 3.94). After 60 sessions, pain scores further decreased by 62.06 percent in the active group (from 7.25 to 2.75) and by only 24.92 percent in the sham group (from 7.10 to 5.33).

Anodal tDCS also reduced the likelihood of requiring analgesics by 55 percent. Higher serum levels of the brain-derived neurotrophic factor predicted higher decreases on the pain scores across treatment.

The findings support the feasibility of home-based tDCS in the treatment of women with fibromyalgia, researchers said. They pointed out that brain-derived neurotrophic factor to index neuroplasticity may be a valuable predictor of the tDCS effect on pain scores decreases across treatment.

Editor's Recommendations
Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.